Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 776 - 800 of 14699 in total
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and ... amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and ... a comparatively favorable adverse effect profile as compared to other available treatment options, and
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for...
Approved
Investigational
Matched Description: … Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. ... [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture …
Matched Categories: … meropenem and vaborbactam …
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Description: … typically associated with a poorer prognosis (as compared to "classical" _EGFR_ mutants causing NSCLC) and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Description: … used to detect ALK and ROS1 rearrangements. ... and genetic resistance mechanisms crizotinib is prone to. ... Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Strontium chloride (SrCl2) is a salt of strontium and chloride. SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. This kind of barrier protection for tooth hypersensitivity has, however, been...
Approved
Matched Description: … Strontium chloride (SrCl2) is a salt of strontium and chloride. ... protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically,...
Approved
Investigational
Matched Description: … Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most ... generally more effective and tolerable than its predecessor. ... synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Matched Description: … are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and
Matched Categories: … Decongestants and Antiallergics …
Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked...
Approved
Investigational
Matched Description: … -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). ... with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and ... [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Matched Description: … Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. …
Matched Categories: … Cough and Cold Preparations …
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and ... It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011 …
Matched Categories: … indacaterol and mometasone ... indacaterol and glycopyrronium bromide ... indacaterol, glycopyrronium bromide and mometasone …
Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calcium-phosphorus metabolism. It is used as an alternative for people developing antibodies against salmon calcitonin.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins …
Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …
Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. ... agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and ... These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Polistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, ... 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary …
Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. Cresols are precursors or synthetic intermediates to various other compounds and materials, including plastics, pesticides, pharmaceuticals, disinfectants, and dyes. Ingestion of cresol induces toxicity...
Approved
Matched Description: … pain, and/or vomiting. ... Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal ... Pure cresol is a mixture of ortho-, meta-, and para- isomers. …
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Description: … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. ... is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and ... This drug was approved after being designed as an orphan drug with a fast track and priority review status …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Karaya gum allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Equipment and Supplies ... Alimentary Tract and Metabolism …
Etofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued .
Approved
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …
Approved
Experimental
Matched Categories: … Blood and Blood Forming Organs …
Cinnamyl alcohol is a naturally occurring compound that is found within cinnamon. Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as DB14184 within commercial products. Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% . Sensitivity...
Approved
Experimental
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. Bulevirtide, also known as Hepcludex, is a...
Approved
Investigational
Matched Description: … of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. ... Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development ... first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying drugs 776 - 800 of 14699 in total